CSU lands $1.2 million in NIH funding to advance work on a new tuberculosis vaccine – Source

At CSU, the research will include a multidisciplinary team of at least 20 researchers, students and staff, including Assistant Professors Michael Lyons and Brooke Anderson, Research Scientists Carolina Mehaffy and Andres Obregon Henao, Associate Professor Diane Ordway, and Corey Broeckling, director of the Proteomics and Metabolomics Facility.

Henao-Tamayo, whose TB research has been focused on vaccines, said the project aims to combine expertise from all over the world. It will include experiments to better understand previous research she conducted in collaboration with the late Ian Orme, a CSU University Distinguished Professor, to study environmental mycobacteria, which live in water and soil, and how these organisms may interfere immunologically with the protection that the BCG vaccine provides against TB.

Podell, who earned doctorates in veterinary medicine and pathology from CSU, said the initiative will be perhaps the most comprehensive pathology assessment of vaccine and TB immunity ever done.

Podell and Henao-Tamayo said that the award reflects not only the outstanding reputation of CSUs Mycobacteria Research labs, but also provides a boost of recognition for the program.

Brendan and I were both trained in these labs, and were now leading the charge on this new research, said Henao-Tamayo.

Additional partners include Oxford University; Public Health England; Statistical Center for HIV/AIDS Research and Prevention at Fred Hutchinson Cancer Research Center; Ragon Institute of MGH, MIT and Harvard; Denver Veterans Affairs Medical Center; National Jewish Health in Denver, and La Jolla Institute for Immunology.

NIAID recently awarded contracts totaling $30 million for the first year to provide up to seven years of support for three Immune Mechanisms of Protection Against Mycobacterium tuberculosis (IMPAc-TB) Centers. The Centers aim to better explain the immune responses required for protection from TB-causing Mycobacterium tuberculosis bacteria. Harvard T.H. Chan School of Public Health and Seattle Childrens Hospital will lead research for the other two centers.

Excerpt from:
CSU lands $1.2 million in NIH funding to advance work on a new tuberculosis vaccine - Source

Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day – Yahoo Finance

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Guggenheim Healthcare Talks Neuro/Immunology Day on Monday, November 18 at 1:00 p.m. ET.

A live webcast of the presentation will be available on the Events and Presentations page in the Investors section of the companys website at https://ir.gossamerbio.com. A replay of the webcast will be archived on the companys website for 90 days following the presentation.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005228/en/

Go here to read the rest:
Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day - Yahoo Finance

Anaphylaxis patients forced to wait more than a year for testing – The Canberra Times

news, latest-news, allergies, allergy, anaphylaxis, food allergies, allergy inquiry, immunology

Those living with life-threatening allergies are being forced to wait up to more than a year just to receive treatment, with experts saying wait times are set to get even worse. As the number of adults being diagnosed with anaphylaxis increases, immunologists and allergy specialists are reporting they are often unable to keep up with demand for testing and treatment. Allergy and Anaphylaxis Australia chief executive Maria Said said allergy sufferers seeking a diagnosis and specialist testing from immunologists are being put at risk due to the increased wait times. "When you have a life-threatening reaction, it could be between 12 and 18 months before an appointment, and that's really unacceptable considering the impact that allergic diseases have on people's quality of life," Ms Said said. "This has the potential to be a lot worse." A study from the Australian Society of Clinical Immunology and Allergy found 10 per cent of infants, up to 8 per cent of children and 2 per cent of adults reported having some form of food-related allergy. A National Health Survey from 2015 also found 3.1 per cent of Australians reported an "undefined allergy", with other forms of anaphylaxis including exposure to mould, insect bites or latex. Ms Said said increased wait times were being seen across Australia, with even longer wait times out of the major capital cities. A spokeswoman for Canberra Health Services said data on average wait times to see ACT-based immunologists was not collected. "Immunologists also deal with patients with other conditions, including serious autoimmune and inflammatory diseases and immune deficiencies," the spokeswoman said. "As a result, there is considerable demand for appointments. There are six immunologists employed by Canberra Health Services, all with part-time appointments." Canberra immunologist Dr Raymond Mullins said while wait times vary from state to state, public hospital outpatient waiting lists are normally more than 12 months. "Food allergies and anaphylaxis have moved from a marginal phenomena to an ongoing public health issue for an increasing proportion of the population and their caregivers," Dr Mullins said. "This has implications in terms of cost of care, the need for medical visits and review, the use and availability of emergency medication such as EpiPens." While data from the ACT is not available, figures from Victoria showed a median waiting time of more than 100 days to access immunologists for allergy testing. Dr Mullins said more people were in need of seeing immunologists as children who developed allergies got older. "Young children who have nut allergies will generally still have persistent food allergy 80 per cent time," he said. "That means we have an ageing population of teenagers and young adults with persistent food allergy at greater risk of having more serious reactions including fatalities." Ms Said said as more adults were experiencing severe allergies, many immunology clinics have been unable to keep up with demand, with many clinics only specialising in paediatrics. "There's only a handful of public clinics, and most are specifically for children, yet there's a growing number of adults with allergic diseases," she said. "It's very concerning because allergic diseases can't be cured and it has to be managed, and people need to be educated on how it can be managed." READ MORE: The access to treatment for those with anaphylaxis forms part of a federal government inquiry into severe allergies. In its submission to the inquiry, the federal Health Department said Australia had one of the highest rates of allergies and anaphylaxis in the world. "Available evidence from hospital admissions for anaphylaxis indicates the prevalence has increased in many western countries, including Australia," the department said. "Total hospital admissions rates for all causes of anaphylaxis increased by 8 per cent each year between 1997 and 2013." The Australian Society of Clinical Immunology and Allergy has told the inquiry the current access process for immunology testing was time-consuming and complicated, calling for access to be simplified. Ms Said said more public clinics were needed in order to reduce wait times for those with anaphylaxis. "We need them especially in rural and remote areas to allow for greater access to an accurate diagnosis and accurate information on allergy management," she said.

https://nnimgt-a.akamaihd.net/transform/v1/crop/frm/fdcx/doc715sqbsljww17409n8yp.jpg/r17_381_3989_2625_w1200_h678_fmax.jpg

SUBSCRIBER

November 18 2019 - 4:30AM

Those living with life-threatening allergies are being forced to wait up to more than a year just to receive treatment, with experts saying wait times are set to get even worse.

As the number of adults being diagnosed with anaphylaxis increases, immunologists and allergy specialists are reporting they are often unable to keep up with demand for testing and treatment.

Allergy and anaphylaxis patients are being forced to wait months to see public immunologists and specialists. Picture: Elesa Kurtz

Allergy and Anaphylaxis Australia chief executive Maria Said said allergy sufferers seeking a diagnosis and specialist testing from immunologists are being put at risk due to the increased wait times.

"When you have a life-threatening reaction, it could be between 12 and 18 months before an appointment, and that's really unacceptable considering the impact that allergic diseases have on people's quality of life," Ms Said said.

"This has the potential to be a lot worse."

A study from the Australian Society of Clinical Immunology and Allergy found 10 per cent of infants, up to 8 per cent of children and 2 per cent of adults reported having some form of food-related allergy.

A National Health Survey from 2015 also found 3.1 per cent of Australians reported an "undefined allergy", with other forms of anaphylaxis including exposure to mould, insect bites or latex.

Ms Said said increased wait times were being seen across Australia, with even longer wait times out of the major capital cities.

Food allergies have shifted from being a fringe issue to a major public health concern. Picture: Shutterstock

A spokeswoman for Canberra Health Services said data on average wait times to see ACT-based immunologists was not collected.

"Immunologists also deal with patients with other conditions, including serious autoimmune and inflammatory diseases and immune deficiencies," the spokeswoman said.

"As a result, there is considerable demand for appointments. There are six immunologists employed by Canberra Health Services, all with part-time appointments."

Canberra immunologist Dr Raymond Mullins said while wait times vary from state to state, public hospital outpatient waiting lists are normally more than 12 months.

"Food allergies and anaphylaxis have moved from a marginal phenomena to an ongoing public health issue for an increasing proportion of the population and their caregivers," Dr Mullins said.

"This has implications in terms of cost of care, the need for medical visits and review, the use and availability of emergency medication such as EpiPens."

The availability of EpiPens is now a core health concern for public institutions. Picture: Shutterstock

While data from the ACT is not available, figures from Victoria showed a median waiting time of more than 100 days to access immunologists for allergy testing.

Dr Mullins said more people were in need of seeing immunologists as children who developed allergies got older.

"Young children who have nut allergies will generally still have persistent food allergy 80 per cent time," he said.

"That means we have an ageing population of teenagers and young adults with persistent food allergy at greater risk of having more serious reactions including fatalities."

Ms Said said as more adults were experiencing severe allergies, many immunology clinics have been unable to keep up with demand, with many clinics only specialising in paediatrics.

"There's only a handful of public clinics, and most are specifically for children, yet there's a growing number of adults with allergic diseases," she said.

"It's very concerning because allergic diseases can't be cured and it has to be managed, and people need to be educated on how it can be managed."

The access to treatment for those with anaphylaxis forms part of a federal government inquiry into severe allergies.

In its submission to the inquiry, the federal Health Department said Australia had one of the highest rates of allergies and anaphylaxis in the world.

"Available evidence from hospital admissions for anaphylaxis indicates the prevalence has increased in many western countries, including Australia," the department said.

"Total hospital admissions rates for all causes of anaphylaxis increased by 8 per cent each year between 1997 and 2013."

The Australian Society of Clinical Immunology and Allergy has told the inquiry the current access process for immunology testing was time-consuming and complicated, calling for access to be simplified.

Ms Said said more public clinics were needed in order to reduce wait times for those with anaphylaxis.

"We need them especially in rural and remote areas to allow for greater access to an accurate diagnosis and accurate information on allergy management," she said.

Here is the original post:
Anaphylaxis patients forced to wait more than a year for testing - The Canberra Times

Top 10 Global Universities for Biology and Biochemistry – Yahoo Finance

Explore schools that excel in biology and biochemistry.

Students might pursue a degree in biology or biochemistry as a path to medical school or a variety of professions. Whatever their career goals, prospective students can explore the top 10 Best Global Universities for Biology and Biochemistry, as ranked by U.S. News based on academic research performance in this subject area.

10. Cornell University

Location: Ithaca, New York

Best Global Universities overall rank: 23

Fact: Cornell University offers multiple college majors that relate to biology and biochemistry, including biology and society, chemistry and chemical biology, biomedical engineering, biological sciences and biological engineering.

9. Johns Hopkins University

Location: Baltimore

Best Global Universities overall rank: 11

Fact: Johns Hopkins University conducted $2.56 billion in medical, science and engineering research in the fiscal year 2017, according to its website.

8. University of California--San Diego

Location: La Jolla, California

Best Global Universities overall rank: 19

Fact: The University of California--San Diego's biological sciences division has more than 100 research labs, according to its website.

7. University of Oxford

Location: Oxford, England

Best Global Universities overall rank: 5

Fact: The University of Oxford's biochemistry department offers a four-year program for undergrads that culminates in a master's credential, according to the department's website.

5 (tie). University of Cambridge

Location: Cambridge, England

Best Global Universities overall rank: 9

Fact: The University of Cambridge's department of biochemistry is home to more than 50 research groups investigating "how cells and their constituent molecules work in life and relate to disease," according to the institution's website.

5 (tie). University of California--San Francisco

Location: San Francisco

Best Global Universities overall rank: 15

Fact: For globally minded students, the University of California--San Francisco offers a one-year master's program in global health and a doctoral program in global health sciences, according to the school's website.

4. University of California--Berkeley

Location: Berkeley, California

Best Global Universities overall rank: 4

Fact: The University of California--Berkeley has six field stations for biology researchers in places as close as San Jose, California, and as far as French Polynesia, according to the school's website.

3. Stanford University

Location: Stanford, California

Best Global Universities overall rank: 3

Fact: During the 2017-2018 school year, human biology was the second most popular undergraduate major at Stanford University, according to the institution's website. Computer science was the most popular.

2. Massachusetts Institute of Technology

Location: Cambridge, Massachusetts

Best Global Universities overall rank: 2

Fact: Three members of the Massachusetts Institute of Technology's biology department faculty are recipients of the Nobel Prize in physiology or medicine, according to the university's website.

1. Harvard University

Location: Cambridge, Massachusetts

Best Global Universities overall rank: 1

Fact: Harvard University is affiliated with 19 hospitals and health-focused research institutes in the Boston area, per its website, creating many opportunities for student research in life sciences fields.

These are the top 10 global universities for biology and biochemistry.

-- 1. Harvard University

-- 2. Massachusetts Institute of Technology

-- 3. Stanford University

-- 4. University of California--Berkeley

-- 5 (tie). University of California--San Francisco

-- 5 (tie). University of Cambridge

-- 7. University of Oxford

-- 8. University of California--San Diego

-- 9. Johns Hopkins University

-- 10. Cornell University

Learn more about studying overseas.

Learn about global universities that offer free or very low tuition, and find out how to account for the language of instruction at global schools. Follow U.S. News Education on Facebook and Twitter for more education rankings and advice.

More From US News & World Report

Excerpt from:
Top 10 Global Universities for Biology and Biochemistry - Yahoo Finance

Relay Therapeutics Strengthens Leadership Team with Key Team Appointments in Research and Development – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, today announced that Ben B. Wolf, M.D., Ph.D., has joined as chief medical officer, Mrunal Monica Phadnis has joined as vice president of clinical operations and Iain Martin, Ph.D., has joined as vice president, drug metabolism and pharmacokinetics.

As we advance multiple programs into the clinic in the coming year and continue to deepen our early stage pipeline, Bens extensive experience in clinical development and translational medicine, Monicas background in clinical operations, and Iains expertise in drug discovery will be critical in helping propel the company in the next phase of our growth, said Don Bergstrom, M.D., Ph.D., executive vice president and head of research and development of Relay Therapeutics. We are pleased to welcome these respected leaders, who together bring a wealth of expertise to our growing team.

Dr. Ben B. Wolf is a precision oncologist who brings to Relay Therapeutics nearly 20 years of experience in the biopharmaceutical industry, with expertise advancing new oncology programs in the clinic and optimizing patient selection to enable rapid proof of concept and registration. He has authored more than 30 peer-reviewed publications and multiple patents related to drug discoveries. Most recently, Dr. Wolf served as chief medical officer at KSQ Therapeutics, a biotechnology company advancing a pipeline of CRISPR-based tumor- and immune-focused drug candidates for the treatment of cancer. Prior to KSQ, Dr. Wolf was senior vice president, clinical development at Blueprint Medicines, where he advanced three oncology programs for novel kinase inhibitors from investigational new drug (IND) applications to clinical proof-of-concept. Prior to Blueprint, Dr. Wolf held clinical and medical director roles at Merrimack Pharmaceuticals, ImmunoGen, Amgen and Genentech. Dr. Wolf holds an M.D. and Ph.D. in biochemistry from the University of Virginia and a B.S. from Union College. He completed medical training in internal medicine and medical oncology at the University of California at San Diego.

Monica Phadnis is an end-to-end delivery expert with more than 15 years in clinical oncology research. Prior to joining Relay Therapeutics, she was the executive director of clinical development in oncology and hematology at Syneos Health, where she worked primarily on early phase solid tumors. Before Syneos, she was the director and clinical operations lead at EMD Serono, where she led Precision Medicine clinical programs in Non-Small Cell Lung Cancer. Additionally, she held roles of growing responsibility at Quintiles Translational Corporation, Sanofi-Aventis, Memorial Sloan-Kettering Cancer Center and Selventa Inc. Ms. Phadnis received a B.S. in mathematics from the University of Mumbai in Mumbai, India and a pre-medical diploma with specialization in genetics from Harvard University.

Dr. Iain Martin brings to Relay Therapeutics more than 30 years of experience in pharmaceutical drug metabolism and pharmacokinetics (DMPK) across therapeutic areas, including oncology and neuroscience. Prior to joining Relay Therapeutics, he was executive director within the department of pharmacokinetics, pharmacodynamics and drug metabolism at Merck, where he led groups responsible for DMPK support of small molecule and peptide programs across the company. Prior to Merck, Dr. Martin held roles of increasing responsibility at The Upjohn Company, AstraZeneca, Organon and Schering Plough. He received his Ph.D. in drug metabolism and a B.S. in biochemistry from the University of Surrey (UK).

About Relay TherapeuticsRelay Therapeutics is committed to creating medicines that will have a transformative impact on patients by building a unique discovery platform centered on understanding how the conformation of proteins relate to function. Whereas prior approaches to imaging proteins have been limited to static pictures, Relay Therapeutics approach overcomes this challenge by combining unprecedented computational power with leading edge experimental techniques in structural biology, biophysics, chemistry and biology. This integration illuminates for the first time the full mobility of a protein and provides key insights into how the dynamic nature of a proteins conformation regulates function. By applying these insights, Relay Therapeutics aims to modulate protein conformation to develop novel therapies for patients. The companys initial programs are focused on developing therapeutics in oncology. Headquartered in Cambridge, Massachusetts, Relay Therapeutics is a private company launched in 2016. To date the company has raised $520M from investors including SoftBank Vision Fund, Third Rock Ventures, Casdin Capital, GV, BVF Partners, EcoR1 Capital, Foresite Capital, Perceptive Advisors, Tavistock Group and an affiliate of D.E. Shaw Research.

See the rest here:
Relay Therapeutics Strengthens Leadership Team with Key Team Appointments in Research and Development - Business Wire

Biochemistry Analysers Market 2025: Topmost manufacturers With Size, Regions, Types, Major Drivers, Profits – VaporBlash

The company provides a detailed analysis of the market and future aspects of the Biochemistry Analysers Market. It focuses on critical and critical data that makes it a very important tool for research, experts, analysts, and managers to achieve ready-to-access analysis. The report provides an inclusive analysis of the Biochemistry Analysers market size forecast from 2018-2025.

Sample report can be viewed in a PDF form by visiting @ researchunt.com/report/global-biochemistry-analysers-market-insights-forecast-to-2025/#Free-Sample-Report

The report embraces the complete information of the key players involved in the worldwide Biochemistry Analysers market. In addition, it provides its market share by various regions with the company and product introduction and their position in the Biochemistry Analysers market. In addition, the report takes into account recent marketing developments as well as their marketing strategies along with an overall business overview. In addition, the report covers market growth factors and restraints of this market.

Prominent players of Biochemistry Analysers market:

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Regional Segmentation for Biochemistry Analysers market:

There are 10 chapters to put on view for Biochemistry Analysers market:

Chapter 1: Consumption by Regions

Chapter 2: Production, By Types, Revenue and Market share by Types

Chapter 3: Consumption, By Applications, Market share (%) and Growth Rate by Applications

Chapter 4: Complete profiling and analysis of Manufacturers

Chapter 5: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses

Chapter 6: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 7: Marketing Strategy Analysis, Distributors/Traders

Chapter8: Market Effect Factors Analysis

Chapter9: Market Forecast

Chapter 10: Biochemistry Analysers Research Findings and Conclusion, Appendix, methodology and data source

Check here for the [emailprotected] researchunt.com/report/global-biochemistry-analysers-market-insights-forecast-to-2025/#Buying-Enquiry

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Follow this link:
Biochemistry Analysers Market 2025: Topmost manufacturers With Size, Regions, Types, Major Drivers, Profits - VaporBlash

Everything you need to know about Victoria Beckhams first skincare product launching tomorrow – Evening Standard

The latest lifestyle, fashion and travel trends

He is one of the most googled names in beauty, and she, one of the most prominent figures in fashion.

It was therefore a fitting match for Victoria Beckham to join forces with Augustinus Bader the notoriously publicity-shy director of stem cell biology and cell technology at the University of Leipzig for her first foray in to skincare.

Bader became a household beauty name in February 2018, after the launch of his cult-product The Cream caused convulsions of desire to ripple throughout the beauty industry thanks to its ultra-hydrating and restorative qualities.

And so when looking for a scientific collaborator to join her on her endeavour in to skincare, it seemed a natural fit for the two to merge theircomplementingareas of expertise.

The Cell Rejuvenating Priming Moisturizer (Victoria Beckham Beauty)

Cue the result of the pairing: Victoria Beckham Beautys Cell Rejuvenating Priming Moisturizer.

The moisturiser is the new-and-improved iteration of the Morning Aura Primer Beckham launched as part of her collaboration with Este Lauder in 2016.

The product, which Beckham has re-developed with the help of 59-year-old Bader, is a multifunctional cream thatclaims to prime, impart a glow and also to repair.

Commenting on the collaborative beauty effort, Beckham took to her Instagram page to note: It has been a dream to develop, with Augustinus, a priming moisturizer that works to improve the health of my skin and gives that fresh, natural glow that I love.

Meanwhile Bader said: "It was an honour to collaborate with Victoria for her first Skin launch. I'm excited to share some of our skincare benefits in this product. It's the first product of its kind to care for your skin cells while also preparing your skin for makeup application."

A celebrity facialist has revealed VB's 9-step daily skincare routine

This marks the first skincare product 45-year-old Beckham has launched under her beauty line, which she debuted to critical-acclaim in September, alongside the brands co-founder, Sarah Creal.

Victoria Beckham Beauty has the tagline Luxury Performance, Clean Beauty, and is refusing to pigeonhole itself as just a beauty brand, instead referring to itself as clean beauty movement.

Cell Rejuvenating Priming Moisturizer costs 92 for 30ml and launches tomorrow exclusively at victoriabeckhambeauty.com and augustinusbader.com.

Go here to see the original:
Everything you need to know about Victoria Beckhams first skincare product launching tomorrow - Evening Standard

Examining the ethics of scientific discovery – Cupertino Today

Posted By: Staff WriterNovember 18, 2019

With artificial intelligence and genetic engineeringcontinuing to shape the future of scientific innovation and discovery,questions about the ethical implications only seem to get more complicated.

Additionally, CRISPR a tool for DNA sequencing and geneediting is bringing new technological changes and advancements in a rapidlyshifting landscape.

A panel discussion at Stanford University later thisweek, moderated by Russ Altman a professor of Bioengineering, Genetics,Medicine, Biomedical Data Science and Computer Science at the university, seeksto discuss how AI and CRISPR are influencing these ethical quandaries and howthey might influence the evolutionary process.

The two panelists for the free, sold-out event areleaders in the field. Jennifer Doudna, a professor of chemistry and molecularand cell biology at UC Berkeley, helped discover CRISPR-Cas9. Fei-Fei Li is acomputer science professor at Stanford in the universitys Institute forHuman-Centered Artificial Intelligence. She previously worked at the schoolsAI Lab and at Google.

The Institute for Human-Centered Artificial Intelligenceis hosting for forum at Stanfords CEMEX Auditorium, 655 Knight Way. It is setfor Tuesday, November 19, from 7 to 8:30 p.m.

While the event has sold out of pre-registration tickets,limited general admission will be available at the site. It will also belivestreamed.

To see more details, click here.

To watch the livestream, click here.

Originally posted here:
Examining the ethics of scientific discovery - Cupertino Today

Poem of the week: Ablation by Helen Mort – The Guardian

Ablation

Inside the Northern Generaltheyre trying to burn awaya small piece of your heart.

I want to know which bit,how muchand what it holds.

My questions livebetween what doctors call the heartand what we mean by it,

wide as the gap between brain and mind.And in our lineage of bypassed heartswe should be grateful

for the literal. I know my heartis your heart good for running,not much else

and later as you sit up in your borrowed bedI get the whole thing wrong,call it oblation. Offering

or sacrice. As if youd given something up.As if their tiny re was ritualand we could warm by it.

Not everyone who writes and reads poetry is a horse-drawn arts person, with zero knowledge of the sciences beyond a little light Googling, but there are still plenty of us around. And we shouldnt despise the online toe-dipping so readily available to science outsiders: it can still energise curiosity and develop brain power. The internet is a friendly sort of school: no one will throw you out for being dumb at quadratic equations or, for that matter, tin-eared to prosody. You can forget assessment, progression, humiliation. You can wing across borders. Its all there, and all connectable, time, patience and imagination permitting.

The same day I discovered this weeks poem while browsing online, I had an email from my daughter, quoting some research on angiogenesis that had recently caught her interest. The paper she quoted, based on research by Bentley and Chakravartula on cell behaviour, made a good case for the hypothesis that cell activity is a perception-action process. In other words, that cells engage in a process analogous to a human moving their eyes or their heads or their bodies to create and interact with variables in optic flow. Cells make decisions! I found this exciting and, although Helen Morts poem deals with a different process, cardiac ablation, I think its special connection of the mechanical and emotional had made me far more receptive to the scientific prose. Both disciplines, poetry and cell biology, seemed to jump out of their respective study rooms and embrace like joyously absconding schoolkids. Reading the poem again after the scientific paper was like hearing a beautifully simple song, a melodic and emotional pattern into which the careful precisions of science had been distilled and shaped.

The speaker in Ablation sits at a hospital bedside, wanting answers to the simple, urgent questions people ask at such times. The questions only seem simple, of course. We know, and the speaker knows, that the heart is not a container for feelings and attributes, and the process of ablation is unlikely to burn away love, courage or good cheer but how do we understand these attributes if they have been displaced from their traditional bodily home? Such questions, the speaker rightly says, live / between what doctors call the heart / and what we mean by it, // wide as the gap between brain and mind.

The stanza break above also indicates the gap between the language lay people use about their bodies and minds, and the objective language of medical science. Sometimes I wonder if the constant anguished discussions in the UK about the failures of the NHS arent only practical in origin, but also reflect a profounder sense of underlying problems communication, as if patient and medical professional spoke across each other in different languages.

Morts poem centres on an ancient definition of the heart, now a well-worn metaphor, and does something almost unbelievably fresh with it. The phrase the lineage of bypassed hearts is particularly suggestive. It may allude to a family history of heart-bypass surgery, or to a habitual evasion of emotion. It seems to include a general and well-grounded fear people have of being reduced in their humanity when they become patients.

The speaker in the poem continues to seek a place for the transcendent. An appropriate conceit the misunderstanding of ablation as oblation enables the process. Its a beautifully economical move to retrieve what the narrator most fears will be lost, allowing the tiny fire of the surgical procedure to become ritual and provide both participants with the literal warmth of their shared love, and their sense of its significance.

You dont have to be Richard Dawkins to disagree profoundly with John Keats (a generally wiser and broader thinker than Dawkins) that Isaac Newton destroyed the rainbow by reducing it to a prism. This poem is not condemning medical science, but asking that an imaginative space be kept open. Emotionally, people need ablation and oblation to be allowed to rhyme.

Ablation is from Helen Morts collection No Map Could Show Them (Chatto & Windus, 2016). Reproduced by permission of the author c/o Rogers, Coleridge & White Ltd, 20 Powis Mews, London W11 1JN.

View post:
Poem of the week: Ablation by Helen Mort - The Guardian

Insufficient Sleep Linked to Biological Aging, Increased Risk of CVD Through Wearable Trackers – AJMC.com Managed Markets Network

The use of wearable trackers found a link in patients reporting insufficient sleep with biological aging and increased risk of cardiovascular disease, according to study findings.

Insufficient sleep has been linked to adverse health outcomes such as obesity, hypertension, CVD, and premature death. The utilization of wearable trackers, which can measure sleep duration and sleep stages with integrated heart rate (HR) sensors, have remained relatively uncharacterized in generating sleep metrics for sleep-related biomedical research. Currently, sleep-health interactions rely on 3 methods to quantify sleep; sleep questionnaires/diaries, actigraphy, and polysomnography (PSG), which the authors noted as all having their distinct limitations.

The growth of wearable trackers from simple and low-cost fitness devices to more sophisticated and multi-functionable smartwatches has increased its potential as a source of accurate data measurement. Prior studies have shown consumer wearables, such as Fitbit and Jawbone, to perform similarly to actigraphs in that they were accurate in detecting sleep but did less well in detecting wake. A previous study by the authors additionally exhibited the efficacy of Fitbit-derived sleep tracking data in showing the differences in sleep patterns among a study cohort.

Researchers sought to expand on the limited research conducted on consumer wearables by addressing a variety of factors not yet examined in previous studies:

The study analyzed questionnaire responses, multi-model phenotypic data, and sleep tracking data generated from Fitbit Charge HR wearables for 482 Singaporean volunteers.

Study results showed that wearable devices, when compared to the PSQI, exhibit independent measures compared to subjective measures of sleep quality. When determining the relationship of wearable-derived sleep metrics to biomarkers such as CVD and LTL, however, a significant association was found in the data.

Multi-model phenotypic data analysis showed that wearable-derived TST and SE were associated with CVD risk markers such as body mass index (TST = 5.683; 95% CI, 1.111 to 2.735;P= .040; SE = 1.089; 95% CI, 2.127 to 5.105;P= .040) and waist circumference (TST = 1.100; 95% CI, 1.499 to 1.720;P= .893; SE = 4.103; 95% CI, 7.169 to 1.036;P= .009), that were not found in self-reported measurements.

For the link between wearable-inferred sleep insufficiency and premature telomere attrition, wearable-derived TST was associated with a measurement of LTL known as quantitative polymerase chain reaction (qPCR) ( = 7.288; 95% CI, 8.318 to 0.001;P= .028), which was not found in the self-reported measurements ( = 0.020; 95% CI, 0.015 to 0.055;P= .258).

Co-lead study author Lim Weng Khong, chief information officer at SingHealth Duke-NUS PRISM and assistant professor in the cancer and stem cell biology program at Duke NUS Medical School, emphasized the study findings for related factors to sleep duration. What we found was that volunteers with enough sleep tended to have longer telomeres compared to those that did not. This was even after accounting for other factors such as age and gender, and provides evidence for a link between chronic sleep deprivation and premature aging, said Khong.

In stressing the efficacy of wearable devices, senior author Patrick Tan, director of SingHealth Duke-NUS PRISM and professor in the cancer and stem cell biology program at Duke-NUS Medical School, said, researchers can leverage wearables to obtain precise data such as sleep patterns more efficiently and can analyze large sets of data at 1 time.

The growing adoption of wearables in Singapore means that more volunteers can contribute data from their own devices, providing further insights into health and disease," said Tan.

Reference

Teo JX, Davila S, Yang C, et al. Digital phenotyping by consumer wearables identifies sleep-associated markers of cardiovascular disease risk and biological aging. Commun Biol. 2019; 2: 361.

View original post here:
Insufficient Sleep Linked to Biological Aging, Increased Risk of CVD Through Wearable Trackers - AJMC.com Managed Markets Network